Confluence Health’s Cancer Research Mission Statement
Confluence Health strives through its cancer research program and clinical trials to provide patients in our rural community access to the most novel and scientifically promising treatments being developed against cancer.
Confluence Health’s Cancer Research Values
Community—We strive to deliver consistent, high-quality, comprehensive cancer care in a community setting.
Caring—We are committed to a steadfast focus on patient safety with compassionate care for the whole patient.
Value—We employ scientifically sound drug development and clinical trial design that leads to the highest opportunity for patient clinical benefit.
Innovation—We are dedicated to developing and improving clinical trial implementation, seeking new ways to advance and bring innovative ideas to reality in a rural community.
Collaboration—We engage in partnerships with like-minded organizations to help us reach our common goals
Oncology Current Studies
• AML – Observational
SCCA 2368 HCT compared to conventional therapy for AML or high risk myelodysplastic syndromes
• AML – Newly Diagnosed FLT3 mutated – ETP
Novartis CPKC412AUS56X – Midostaurin
• Breast, High-Risk, ER+, HER-2 neg
SWOG 1207 Adjuvant endocrine therapy +/- Everolimus
• Breast, locally advanced or metastatic, Triple Neg (0-1 prior lines in advanced setting)
Medivation MDV3100-20 – Enzalutamide in combo with Paclitaxel or monotherapy vs. placebo with Paclitaxel
• Breast Metastatic (MBC)
SCCA 8093 Metronomic Eribulin (Halaven) In Pretreated MBC
• Breast, ER/PR+, HER2 neg, metastatic, progression on AI, 2nd or 3rd Line
Novartis CBYL7192301 Placebo vs alpelisib in combination with fulvestrant
• Breast Metastatic – provider didactic intervention
Fox Chase Cancer Center/NCCN/SCCA
Women at any stage >70 yo
• DLBCL – Untreated ABC Type
R-CHOP +/- Revlimid
• Lung Stage IIIB/IV – Adeno of lung with exon 14 skipping mutation of c-Met (3-4% of pts)
EMD Serono MS200095-0022, Phase 2 single arm – Tepotinib (MSC2156119J) after failure of at least one platinum doublet-containing line of therapy
• Multiple Myeloma – Newly Diagnosed and Treatment Naïve (Transplant Ineligible)
Lenalidomide and Dexamethasone with or without Pembrolizumab (over 65)
• Multiple Myeloma – Relapsed/Refractory
• Pancreatic – Unresectable, Metastatic, Front Line
Ibrutinib/placebo in combination with nab-Paclitaxel and Gemcitabine
• Prostate – Metastatic Hormone sensitive
Astellas mHSPC Enzalutimide + ADT vs placebo + ADT
• Renal Cell (metastatic) Urothelial Gastric (including gastro-esoph adeno) and Colorectal (met)
Prior regiments: RCC min 1/max 4; Urothelial min 1/max 2; Gastric min 1/max 3; CRC min 2/max 4
• Stomach or GEJ Unresectable locally advanced or metastatic
EMR100070-007 Maintenance therapy with avelumab vs continuation first line chemo (mFOLFOX or CAPOX)
Phone: (509) 665-5800
Cancer Research Coordinators:
(509) 663-8711, Ex. 5014
(509) 664-4868, Ex. 2046
Phone: (509) 665-5800
Fax: (509) 664-7177
Address: Confluence Health | Wenatchee Valley Hospital & Clinics, 820 N. Chelan Ave., Wenatchee, WA 98801.